Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 13/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24447202 | 1.00 | CHRM1 (0.47) | CHRM1SIGMAR1JAK3THRBTEAD1 | |
| SCHEMBL23312157 | 0.86 | CHRM1 (0.50) | CHRM1SIGMAR1JAK3THRBCNR1 | |
| SCHEMBL23278116 | 0.84 | JAK3 (0.39) | CHRM1JAK3 | |
| SCHEMBL20334388 | 0.83 | TEAD1 (0.34) | CHRM1JAK3TEAD1BTK | |
| SCHEMBL25840889 | 0.81 | JAK3 (0.41) | JAK3 | |
| SCHEMBL23583942 | 0.81 | JAK3 (0.36) | CHRM1SIGMAR1JAK3 | |
| SCHEMBL27284053 | 0.80 | JAK3 (0.40) | JAK3TEAD1BTK | |
| SCHEMBL23545018 | 0.80 | JAK3 (0.40) | JAK3TEAD1BTK | |
| SCHEMBL25840939 | 0.79 | JAK3 (0.42) | JAK3TEAD1BTK | |
| SCHEMBL23735830 | 0.78 | TEAD1 (0.39) | JAK3TEAD1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | CHRM1 4779/4885SIGMAR1 3400/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.